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Abstract
Background: Although C/EBPb
ko mice are refractory to Bleomycin-induced lung fibrosis the molecular mechanisms remain
unknown. Here we show that blocking the ribosomal S-6 kinase (RSK) phosphorylation of the CCAAT/Enhancer Binding
Protein (C/EBP)-b on Thr217 (a RSK phosphoacceptor) with either a single point mutation (Ala217), dominant negative
transgene or a blocking peptide containing the mutated phosphoacceptor ameliorates the progression of lung injury and
fibrosis induced by Bleomycin in mice.
Methodology/Principal Findings: Mice expressing the non-phosphorylatable C/EBPb-Ala217 transgene had a marked
reduction in lung injury on day-13 after Bleomycin exposure, compared to C/EBPb
wt mice, judging by the decrease of CD68
+
activated monocytes/macrophages, bone marrow-derived CD45
+ cells and lung cytokines as well as by the normal
surfactant protein-C expression by lung pneumocytes. On day-21 after Bleomycin treatment, C/EBPb
wt mice but not mice
expressing the dominant negative C/EBPb-Ala217 transgene developed severe lung fibrosis as determined by quantitative
collagen assays. All mice were of identical genetic background and back-crossed to the parental wild-type inbreed FVB mice
for at least ten generations. Treatment of C/EBPb
wt mice with a cell permeant, C/EBPb peptide that inhibits phosphorylation
of C/EBPb on Thr217 (40 mg instilled intracheally on day-2 and day-6 after the single Bleomycin dose) also blocked the
progression of lung injury and fibrosis induced by Bleomycin. Phosphorylation of human C/EBPb on Thr266 (human
homologue phosphoacceptor) was induced in collagen-activated human lung fibroblasts in culture as well as in activated
lung fibroblasts in situ in lungs of patients with severe lung fibrosis but not in control lungs, suggesting that this signaling
pathway may be also relevant in human lung injury and fibrosis.
Conclusions/Significance: These data suggest that the RSK-C/EBPb phosphorylation pathway may contribute to the
development of lung injury and fibrosis.
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Introduction
The morbidity and mortality, as well as the financial and
personal burden of lung injury and fibrosis are substantial. Lung
fibrosis and the resulting abnormal pulmonary function are
responsible for the associated complications, including pulmonary
hypertension, cardiac failure, lung tumors, and cachexia [1]. All
these complications of lung fibrosis are the main indication for
lung transplantations in the US and worldwide [2]. According to
the National Heart, Lung and Blood Institute, idiopathic
pulmonary fibrosis (IPF) affects 5 million people worldwide and
200,000 patients in the US. No therapy is known to improve
health-related quality of life or survival in patients with IPF [3] and
these patients live only 3 to 5 years after diagnosis [4]. Therefore,
preventing the progression, or inducing regression of lung injury
and fibrosis will have a major potential impact in these patients.
Quiescent lung fibroblast produce negligible amounts of
extracellular matrix proteins (ECM), but after their activation,
these cells develop a myofibroblast phenotype, proliferate and
become the main contributors of ECM [5]–[7]. This step is
important for the development of lung fibrosis [1],[6],[7].
As reported by us and others, C/EBPb
ko mice are refractory to
hepatotoxin-induced liver fibrosis [8] and Bleomycin-induced lung
fibrosis [9]. Although knock-out mice are a valuable initial tool to
determine the general role of gene products, as in the case of C/
EBPb
ko mice being refractory to Bleomycin-induced lung fibrosis,
knockout mice do not allow identification of the molecular
mechanisms downstream from extracellular signaling cues.
Knowledge of the specific signaling involving a single amino acid
within a specific phosphoacceptor domain of the protein (in this
case C/EBPb) is necessary to understand the mechanisms and to
eventually design effective targeted therapeutics that are still
lacking in the treatment of human lung injury and fibrosis
[1],[6],[7].
In this context, the mitogen-activated protein kinase (MAPK)
pathway, through the extracellular signal-regulated kinase
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25497(ERK1/2), activates p-90 RSK [10]–[14], resulting in the
phosphorylation of mouse C/EBPb (NP_034013 XP_916631) on
Thr217(Thr266 in human C/EBPb) as we reported previously
[10],[15]. The RSK phosphoacceptor site in C/EBPb is identical
in mouse and human, and it is evolutionary conserved [15].
We and others have established that site-specific phosphoryla-
tions of C/EBPb are critical modulators of gene expression, cell-
cycle progression, apoptotic programs, immune modulation and
tissue inflammation and repair [8],[10],[15]–[17]. Our central
hypothesis was that the RSK- C/EBPb-Thr217 phosphorylation
pathway may be critical for lung injury and fibrogenesis since as
reported by us and others, this signaling is essential for both the
macrophage inflammatory function [16],[17] and survival of
activated liver myofibroblasts (hepatic stellate cells) [8],[10]. We
proposed that macrophage inflammatory function and survival of
activated lung myofibroblasts may determine the degree of lung
injury and fibrosis.
Chronic Bleomycin treatment can induce lung injury and
fibrosis in humans [18], and Bleomycin treatment is a classical
method of inducing lung injury and fibrosis in mice [9],[18]–[21].
We used this model to investigate the role of RSK and
phosphorylation of C/EBPb on Thr217 in lung injury and
fibrosis. Here we show that inhibition of C/EBPb phosphorylation
on Thr217 (RSK phosphoacceptor) within the transactivation
domain with either a single point mutation (Ala217), dominant
negative transgene or a blocking peptide containing the mutated
phosphoacceptor ameliorates the progression of lung injury and
fibrosis induced by Bleomycin in mice. Phosphorylation of human
C/EBPb on Thr266 (human homologue phosphoacceptor) was
induced in collagen-activated human lung fibroblasts in culture as
well as in activated lung fibroblasts in situ in lungs of patients with
severe lung fibrosis but not in control lungs, suggesting that this
signaling pathway may be also relevant in human lung injury and
fibrosis.
Results
Mice expressing the dominant negative C/EBPb-Ala217
transgene are resistant to Bleomycin-induced lung
fibrosis
Given the important role of RSK and its phosphorylation of C/
EBPb-Thr217 in the activation of liver myofibroblasts (hepatic
stellate cell) [10],[22] and the suggested similarities between liver
and lung fibrogenesis [1],[23], we hypothesized that a dominant
negative, non-phosphorylatable transgenic C/EBPb-Ala217
would block phosphorylation of C/EBPb-Thr217 by RSK,
preventing lung myofibroblast (LMF) activation and decreasing
lung fibrosis after lung injury.
Because the chronic exposure to the lung toxin Bleomycin can
induce lung fibrosis in humans, and it is a classical method of
inducing lung injury and fibrosis in mice [18],[24], we analyzed
whether it induces lung fibrosis in mice expressing the dominant
negative, nonphosphorylatable C/EBPb-Ala217 transgene. This
mutation changes the phosphorylatable Thr217 to a nonpho-
sphorylatable Ala217 within the RSK phosphoacceptor site of C/
EBPb. These animals are developmentally normal, fertile and
have a normal life span as we reported [8],[10] suggesting that the
RSK-inhibitory transgene is apparently not toxic. The transgene is
expressed to a similar degree that the C/EBPb
wt in all tissues
tested to date, including lungs. Specifically, the transgene is
expressed in epithelial cells, macrophages and myofibroblasts. All
the animals used in this study were of the same FVB genetic
background with back-crossing for more than 10 generations
eliminating the important confounding variable of mouse strain
susceptibility to Bleomycin-induced lung fibrosis [25].
On day-21 after the single intratracheal administration of
Bleomycin, we determined the degree of lung fibrosis in coded
samples. This is a significant exposure for mice [18]. We evaluated
lung fibrosis and fibrogenesis employing several complementary
methods: i) trichrome stain; ii) Sirius red stain; iii) quantitative
Sirius red collagen-binding assay [8],[26]; iv) quantitative
hydroxyproline assay; v) quantitative collagen type 1 assay; vi)
expression of a-smooth muscle actin (a-SMA) (present in activated
LMF); and vii) expression of transforming growth factor (TGF)- b1
(a pro-fibrotic cytokine) [1],[5]–[7],[23],[27].
Lung samples were stained with the classical Mallory’s
trichrome to identify collagen in the extracellular matrix. As
expected, the lung collagen pattern and content of C/EBPb
wt
mice on day-21 after Bleomycin treatment were increased
similarly to those previously reported [9],[18]–[21],[25]
(Figure 1A). We graded the coded lung samples with the
standard clinical system (0–3; none, mild, moderate and severe),
and found that after Bleomycin treatment, C/EBPb
wt mice had
moderate to severe lung fibrosis (mean score 2.8+/20.4; n: 10)
compared to controls , while C/EBPb-Ala217 mice of the same
genetic background had mild or moderate lung fibrosis (mean
score: 1.5+/20.5; n: 10; P,0.001; Wilcoxon U Test) (Figure 1A).
In agreement with the findings with the Mallory’s trichrome, the
Sirius red collagen-binding stain under polarized light also
demonstrated decreased lung fibrosis after Bleomycin treatment
in C/EBPb-Ala217 mice (Figure 1B). Although the intra- and
inter-observer variability in the semi-quantitative analysis of lung
fibrosis was low, we confirmed these findings using quantitative
analysis of lung fibrosis.
The quantitative analysis of lung collagen, the major extracel-
lular matrix protein in lung fibrosis [1], with assays for Sirius red
collagen-binding, hydroxyproline and collagen type 1 demonstrat-
ed that C/EBPb-Ala217 mice were refractory to the development
of lung fibrosis after exposure to the lung toxin (Figure 1C, 1D
and 1E). The lung collagen content increased approximately 2- to
8-fold from baseline in C/EBPb
wt mice (n: 7 per group; Sirius red
collagen-binding: 2.8+/20.3; collagen type: 3.6+/20.5; and
hydroxyproline: 8.7+/20.9; P,0.0001 for all), while remaining
closer to baseline in C/EBPb-Ala217 mice treated with Bleomycin
(n: 6; Sirius red collagen-binding: 1.1+/20.2, P=0.37; collagen
type: 1.0+/20.2, P=0.46; and hydroxyproline: 3.1+/21.0,
P=0.002) (Figure 1C, 1D and 1E).
Further, the protein expression of lung fibrogenic indicators a-
SMA, present in activated myofibroblasts (NM_007392.2) and
TGF-b1, a fibrogenic cytokine [27] (NM_009370.2) were induced
by Bleomycin in C/EBPb
wt mice ,5-fold (n: 7 per group; a-SMA:
5.2+/20.3, P,0.0001; TGF-b1: 5.9+/20.3 P,0.0001) but not in
C/EBPb-Ala217 mice (n: 6 per group; a-SMA: 1.2+/20.2,
P=0.15; TGF-b1: 0.7+/20.2, P=0.013) as measured by
immunoblots (Figure 2A and 2B). Pixel intensity was quantified
by the Odyssey Western Infrared Detection Method and Odyssey
Visualization protocol as described previously [28] (Figure 2B).
In summary, expression of the non-phosphorylatable, dominant
negative C/EBPb-Ala217 transgene decreases the fibrogenic
response of the lung to Bleomycin -induced injury (Figures 1
and 2).
Mice expressing the dominant negative C/EBPb-Ala217
transgene are resistant to Bleomycin-induced lung injury
The degree of the initial lung injury, early inflammatory foci
and bone marrow–derived cell activation contribute to the
development of lung fibrosis [6],[7],[18],[19],[29]. Therefore, we
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25497Figure 1. Blocking the C/EBPb-Thr217 phosphorylation ameliorates the induction of lung fibrosis by Bleomycin. FVB C/EBPb
wt mice
received once intracheally either Bleomycin or control saline as described in Methods. Analysis was performed on day-21. The bars represent 50 mm.
A. Representative Mallory’s trichrome stain for lung fibrosis (in blue). We graded the coded lung samples with the standard clinical system (0–3; none,
mild, moderate and severe). After Bleomycin treatment, C/EBPb
wt mice had moderate to severe lung fibrosis compared to controls, while C/EBPb-
Ala217 mice of the same genetic background had mild or moderate lung fibrosis (mean scores : 2.8+/20.4 vs. 1.5+/20.5; n: 10 per group; P,0.001).
Treatment of C/EBPb
wt mice with the C/EBPb peptide (on day-2 and day-6) after Bleomycin treatment ameliorated the lung fibrosis at day-21 (mean
fibrosis score: 2.0+/20.7; n:5 ;P=0.048). B. Representative Sirius red immunohistochemistry for collagen by light microscopy (in red) (L panels) and
with a polarized light (R panels). Increase in lung collagen in a fibrotic pattern was observed in C/EBPb
wt but not in C/EBPb-Ala 217 mice, treated with
Bleomycin. Treatment of C/EBPb
wt mice with the C/EBPb peptide (on day-2 and day-6) after Bleomycin treatment decreased the lung fibrosis at day-
C/EBPb Phosphorylation and Lung Injury
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25497assessed the degree of lung injury and inflammation in response to
the lung toxin.
Decreased surfactant protein-C (SFPC) production by type II
pneumocytes is a sensitive and specific indicator of alveolar
epithelial lung injury in humans and animals [30],[31]. Therefore,
we evaluated lung injury in mice on day-13 after exposure to
Bleomycin by measuring SFPC lung expression. We found that C/
EBPb-Ala217 mice had much less lung injury than C/EBPb
wt
mice after Bleomycin treatment, judging by the SFPC protein
expression as determined by confocal microscopy (Figure 3A) and
quantitative immunoblots (n: 5 per group; 0.81+/20.06 vs 0.04+/
20.25; P=0.006) (Figure 3B and 3C). The expression of SFPC
protein was decreased from baseline by Bleomycin treatment
in both C/EBPb
wt (P=0.0003) and C/EBPb-Ala217 mice
(P=0.0042) (Figure 3B and 3C).
Because the C/EBPb-Ala217 transgene inhibited lung injury
(Figure 3),wedetermined whether lung cytokine proteinexpression
is decreased in C/EBPb-Ala217 mice. We used a multiplex nano-
arrayassaytoassessexpressionofteninflammatorycytokineproteins
in the lungs of control and transgenic mice. As expected, on day-13
Bleomycin induced several fold the protein expression of cytokines
interleukin (IL-1)- a , IL-2, IL-3, IL-4, IL-5, IL-6, IL-10 , tumor
necrosis factor (TNF)- a, interferon (IFN)-c and granulocyte-
macrophage colony-stimulating factor (GM-CSF) in the lungs of
C/EBPb
wt animals (n: 3p e rg r o u p ;P,0.01 for all cytokines)
(Figure 4). The protein cytokine induction was lower in the lungs
fromC/EBPb-Ala217micethaninthe lungsofcontrolmice onday-
13 after Bleomycin–induced lung injury (n: 3p e rg r o u p ;P,0.01 for
all cytokines, except for IL-2; P=0.56) (Figure 4).
In addition, a decreased inflammatory response, mediated at
least in part by monocytes/macrophages in the lungs of C/EBPb
wt
mice may be responsible for the decreased lung injury in C/EBPb-
Ala217 mice treated with Bleomycin (Figure S1) since it also
affected the recruitment to the lung of CD68
+ activated
monocytes/macrophages and bone marrow-derived CD45
+ cells
(Figures S2 and S3). These data suggest that partial resistance to
Figure 2. Blocking the C/EBPb-Thr217 phosphorylation decreases the Bleomycin-induced activation of LMF. Mice were treated with
Bleomycin or saline as described in Methods. Analysis was performed on day-21 A. Immunoblots for a-SMA, TGF-b and b-Actin were performed as
described in Materials and methods. B. Pixel intensity was quantified by the Odyssey Western Infrared Detection Method and Odyssey Visualization
protocol as described in Methods. The fold-increase in protein expression of lung fibrogenic indicators a-SMA and TGF-b1 were induced by
Bleomycin in C/EBPb
wt mice (n: 7 per group; a-SMA: 5.2+/20.3, P,0.0001; TGF-b1: 5.9+/20.3 P,0.0001) but not in C/EBPb-Ala217 mice (n: 6 per
group; a-SMA: 1.2+/20.2, P=0.15; TGF-b1 : 0.7+/20.2 , P=0.013) as measured by immunoblots Treatment of C/EBPb
wt mice with the C/EBPb peptide
(on day-2 and day-6) after Bleomycin treatment also ameliorated the expression of a-SMA protein (1.0+/20.18 , P=0.428) and TGF-b1 protein (1.1+/
20.17, P=0.793). b-Actin was used to correct for lung lysate input. Representative results from three independent studies.
doi:10.1371/journal.pone.0025497.g002
21. C, D and E. Quantitation lung fibrosis was performed by the Sirius red collagen–binding, collagen type 1 and hydroxyproline assays as described
in Methods. The lung collagen content increased (fold from baseline) in C/EBPb
wt mice (n: 7 per group; Sirius red collagen-binding: 2.8+/20.3;
collagen type: 3.6+/20.5; and hydroxyproline: 8.7+/20.9; P,0.0001 for all), while remaining closer to baseline in C/EBPb-Ala217 mice treated with
Bleomycin (n: 6 ; Sirius red collagen-binding: 1.1+/20.2, P=0.37 ; collagen type: 1.0+/20.2, P=0.46; and hydroxyproline: 3.1+/21.0, P=0.002). The
specific fold changes in C/EBPb
wt mice treated with Bleomycin and the C/EBPb peptide included: Sirius red collagen-binding (0.94+/20.2, P=0.80);
collagen type 1 (1.1+/20.2, P=0.934); and hydroxyproline (3.1+/21.0, P=0.002; n: 5 for all groups). Representative results from three independent
studies for the transgenic mice and of two independent studies for the peptide.
doi:10.1371/journal.pone.0025497.g001
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25497lung injury and inflammation may contribute to the prevention of
lung fibrosis in C/EBPb-Ala217 mice.
Mice expressing the dominant negative C/EBPb-Ala217
transgene are resistant to Bleomycin-induced LMF
activation
Quiescent resident lung or bone marrow-derived fibroblasts
produce negligible amounts of ECM, but after their activation,
these cells develop a myofibroblast phenotype, proliferate and
become the main contributors of ECM [1],[6],[7],[19]. Because
this step may facilitate development of lung fibrosis foci [32], we
analyzed the activation and proliferation of LMF in the lungs of
mice on day-21 after exposure to Bleomycin.
As expected, Bleomycin administration to C/EBPb
wt mice,
induced marked activation of LMF, as indicated by the positive
immunofluorescence for a-SMA within the scar tissue [19]
(Figure 5). By contrast, C/EBPb-Ala217 mice were refractory
to the induction of LMF activation by Bleomycin treatment
(Figure 5).
As determined by scanning confocal microscopy, C/EBPb
phosphorylation was negligible in lungs of untreated C/EBPb
wt
mice but it was induced by Bleomycin in these animals but not in
C/EBPb-Ala217 mice (Figures 5 and 6), suggesting that C/
EBPb expression and phosphorylation are associated with
activation of LMF and lung injury. As expected, phosphorylation
of C/EBPb-Thr217 in LMF (a-SMA
+) was induced by Bleomycin
in C/EBPb
wt mice but not in C/EBPb-Ala217 mice (Figure 5).
The phospho-C/EBPb-Thr217 was mainly nuclear but also
cytoplasmic. The cytoplasmic localization is most likely related
to an additional C/EBPb phosphorylation on Ser239, within the
DNA-binding domain, that we have previously characterized [33].
This C/EBPb-Ser239 phosphorylation , which is induced through
oxidative stress and NO , neutralizes the nuclear localization signal
and facilitates the interaction of the nuclear export signal with the
nucleo-cytoplasmic shuttle protein CRM1 [34].
We analyzed immunoblots from C/EBPb immunoprecipitates
of lung lysates (Figure 6A and 6B) using specific antibodies
[8],[10]. Pixel intensity was quantified by the Odyssey Western
Infrared Detection Method and Odyssey Visualization protocol as
described previously [28] (Figure 6B). After Bleomycin admin-
istration, C/EBPb and phosphorylated C/EBPb-Thr217 were
induced several fold in the lungs of C/EBPb
wt mice (n: 6 per
group; C/EBPb: 5.56+/20.52, P,0.0001; phosphorylated C/
EBPb-Thr217: 5.48+/20.37 , P,0.0001), but not in the lungs of
C/EBPb-Ala217 mice (n: 6 per group; C/EBPb: 1.20+/20.11,
P=0.332; phosphorylated C/EBPb-Thr217: 1.10+/20.17, P=
0.510). These studies also demonstrated the increased fold
association between RSK and phosphorylated, activated RSK
with phosphorylated C/EBPb-Thr217 in lungs of C/EBPb
wt mice
treated with Bleomycin (n: 6 per group; RSK: 4.85+/20.31,
P,0.0001; phosphorylated, activated RSK: 5.07+/20.37,
P,0.0001) but not C/EBPb-Ala217 mice treated with Bleomycin
(n: 6 per group; RSK: 0.87+/20.12, P=0.242; phosphorylated,
activated RSK: 1.01+/20.21, P=0.633) (Figure 6B). Phosphor-
ylated, activated RSK was co-localized with phosphorylated C/
EBPb-Thr217 by confocal microscopy in lungs of C/EBPb
wt mice
treated with Bleomycin but not in the lungs of C/EBPb-Ala217
mice treated with Bleomycin (Figure 7). C/EBPb was induced in
C/EBPb
wt mice by Bleomycin as C/EBPbD154 (LIP) an
alternative, shorter translation product initiated at the third
AUG codon of the C/EBPb mRNA, that shares with C/EBPb
the Thr-217 phosphoacceptor, the DNA binding and leucine
zipper domains [35]. The expression of full-length C/EBPb from
the second AUG in the lungs of C/EBPb
wt mice and C/EBPb-
Ala217 transgene was minimal at baseline and not induced by
Bleomycin treatment.
Unphosphorylated C/EBPb-Thr217 is associated with
members of the active caspase 8 death receptor complex
II in the lungs of Bleomycin -treated animals
We found that the fold association between C/EBPb with active
caspase 8 was greater in the lungs from C/EBPbAla217 mice after
Bleomycin administration (n: 6 per group; active caspase 8: 5.65+/
20.40, P,0.0001) that in the lungs from C/EBPb
wt mice after
Bleomycin administration (n: 6 per group; active caspase 8: 0.99+/
20.12, P=0.362) (Figure 6A and 6B). The increased activation
of initiator caspase 8 (Figure 6) , and RIP, a member of the
caspase 8 complex II (Figure S4), in the lungs of the nonpho-
sphorylatable C/EBPb-Ala217 mice after Bleomycin administra-
tion is congruent with our report that phospho-C/EBPb-Thr217
inhibits procaspase 8 activation, and that blocking this site-specific
phosphorylation results in activation of caspase 8 [10],[36].
Unphosphorylated C/EBPb-Thr217 is associated with
active caspase 8 and induction of cell death pathways in
activated human lung fibroblasts
Because the mixed cell population of the lung limits the
evaluation of signaling cascades in a specific cell type, we studied
the fibrogenic pathway in cultured primary human lung
fibroblasts. The lung fibroblasts were activated on collagen type
1, a condition that recapitulates the activation of LMF in vivo, and
identified by their expression of a-SMA [1],[6],[7],[19]. Because
myofibroblasts from IPF patients are already abnormally activated
and they would not allow analysis of the transition into activated
LMF [1],[6],[7],[19], as a proof of principle we used lung
fibroblasts derived from normal lungs. A similar strategy using
normal, quiescent myofibroblasts has been effective in developing
activated myofibroblasts from the liver and other tissues
[8],[10],[23].
We found that an ERK1/2 inhibitor that blocks the MAPK
signaling immediately upstream of RSK and prevents C/EBPb-
Figure 3. Mice expressing the C/EBPb-Ala217 transgene are refractory to the induction of lung injury. C/EBPb
wt and C/EBPb-Ala217
mice received once intracheally either Bleomycin or control saline as described in Methods. Analysis was performed on day-13. The bars represent
50 mm. A. Representative examples of the expression of Surfactant Protein C (SFPC), identified by confocal microscopy (red). It was decreased in the
lungs of C/EBPb
wt mice treated with Bleomycin, but not in the lungs of C/EBPb-Ala217 mice treated with Bleomycin or in the lungs of C/EBPb
wt
treated with Bleomycin and the C/EBPb peptide as described in Methods. Nuclei are identified with TO-PRO-3 (blue). Only background staining was
observed when omitting the first antibody. B. Expression of SFPC as determined by immunoblots as described in Methods. C. Pixel intensity was
quantified in a Kodak-4000 Imaging Station as described in Methods. C/EBPb-Ala217 mice had much less lung injury than C/EBPb
wt mice after
Bleomycin treatment (n: 5 per group; 0.81+/20.06 vs 0.04+/20.25; P=0.006). The expression of SFPC protein was decreased from baseline by
Bleomycin treatment in both C/EBPb
wt (P=0.0003) and C/EBPb-Ala217 mice (P=0.0042). C/EBPb
wt mice that received the C/EBPb peptide had less
lung injury than control C/EBPb
wt mice after Bleomycin treatment, judging by the SFPC expression (n: 5; 0.78+/20.05 vs 0.04+/20.25; P=0.008). The
expression of SFPC protein was decreased from baseline by Bleomycin treatment in animals receiving the peptide (P=0.0019). b-Actin was used to
correct for lung lysate input. Representative results from two independent studies.
doi:10.1371/journal.pone.0025497.g003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25497Figure 4. Mice expressing the C/EBPb-Ala217 transgene are refractory to the induction of lung inflammation. Animals received either a
single intratracheal instillation of Bleomycin or saline as described in Methods. On day-13 , Bleomycin induced several fold the protein expression of
cytokines IL-1-a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, TNF-a, IFN-c and GM-CSF in the lungs of C/EBPb
wt animals (n:3 per group; P,0.01 for all cytokines). The
protein cytokine induction was lower in the lungs from C/EBPb-Ala217 mice than in the lungs of C/EBPb
wt mice on day-13 after Bleomycin–induced
lung injury (n: 3 per group; P,0.01 for all cytokines, except for IL-2; P=0.56). C/EBPb
wt mice that received the C/EBPb peptide had less lung
inflammation than control C/EBPb
wt mice after Bleomycin treatment (n: 3 per group; P,0.05 for all cytokines).
doi:10.1371/journal.pone.0025497.g004
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25497Thr266 phosphorylation (identical to mouse phosphoacceptor
Thr217) [8], decreased the fold expression of RSK (n:6 per group ;
0.07+/20.01, P,0.0001), C/EBPb (n: 6 per group; 0.05+/
20.006, P,0.0001) and C/EBPb-PhosphoThr266 (n: 6 per
group; 0.33+/20.078, P,0.0001) in activated, human lung
fibroblasts (Figure 8A and 8B). Moreover, in these activated,
human lung fibroblasts treated with the ERK1/2 inhibitor, there
was also an increased fold association between unphosphorylated
human C/EBPb (NP_005185) and active caspase 8 (n: 6 per
group; active caspase 8: 5.70+/20.59 , P,0.0001) (Figure 8A
and 8B). In contrast, in activated, human lung fibroblasts
untreated with the ERK1/2 inhibitor, C/EBPb-Thr266 was
phosphorylated and associated with procaspase 8 (Figure 8A and
8B). The RSK phosphoacceptor site in human C/EBPb-Thr266
appears to be essential for preventing activation of death cascades
in lung fibroblasts upon their activation. The cultured human lung
fibroblasts expressed mainly C/EBPbD154 and to a lesser degree
full-length C/EBPb translated from the second AUG [35].
Further, the ERK1/2 inhibitor decreased the fold expression of
protein indicators of activated, human lung fibroblasts as
measured by quantitative immunoblots (n: 6 per group; a-SMA:
0.05+/20.03, P,0.0001; TGF-b1: 0.03+/20.01 P,0.0001)
(Figure 8C and 8D). In addition, activated, human lung
fibroblasts treated with the ERK1/2 inhibitor displayed increased
percent annexin-V binding to phosphatidylserine in plasma
membranes (n: 6 per group; annexin-V binding: 4.15+/20.94%
vs 66.33+/25.68%, P,0.0001), an early indicator of apoptosis
[10] (Figure 8E).
In summary, blocking phosphorylation of human C/EBPb-
Thr266 through the inhibition of the MAPK signaling upstream of
RSK with the ERK1/2 inhibitor decreases the fibrotic response
(Figure 8C and 8D) and induces the apoptotic program
(Figure 8A, 8B and 8E) in activated primary human lung
fibroblasts.
Next, we assessed whether the cell permeant Ac-KAla217VD-
CHO peptide that inhibits phosphorylation of human C/EBPb-
Thr266 [8],[10] would have similar effects that the ERK1/2
inhibitor on activated, normal human lung fibroblasts. As we
found with the ERK1/2 inhibitor, the peptide also inhibited C/
EBPb expression (n: 6 per group; 0.12+/20.01, P,0.0001), the
phosphorylation of C/EBPb-Thr266 (n: 6 per group; 0.17+/
20.03 , P,0.0001), the association of RSK with C/EBPb (n: 6 per
group; 0.24+/20.08, P,0.0001) (Figure 8A and 8B), the
expression of a-SMA (n: 6 per group; 0.24+/20.11, P,0.0001)
and TGF-b1 (n: 6 per group; 0.14+/20.02, P,0.0001)
(Figure 8C and 8D), but increased the association of active
caspase 8 with C/EBPb (n: 6 per group; 6.15+/20.27, P,0.0001)
(Figure 8A and 8B) as well as the induction of apoptosis
(n: 6 per group; 4.15+/20.94% vs 61.00+/29.27%, P,0.0001)
(Figure 8E).
Figure 5. Mice expressing the C/EBPb-Ala217 transgene are refractory to lung myofibroblast activation. Mice were treated with
Bleomycin as described in Materials and methods. Analysis was performed on day-21 The bars represent 50 mm. A. Activated LMF, identified by
confocal microscopy for a-smooth muscle actin (a-SMA; red), displayed C/EBPb-PhosphoThr217 (green) in lungs of C/EBPb
wt treated with Bleomycin,
but not in lungs of C/EBPb-Ala217 mice treated with Bleomycin or in the lungs of C/EBPb
wt treated with Bleomycin and the C/EBPb peptide. Co-
localization of a-SMA and C/EBPb-PhosphoThr217 is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue). Only background staining
was observed when omitting the first antibody.
doi:10.1371/journal.pone.0025497.g005
C/EBPb Phosphorylation and Lung Injury
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25497Figure 6. Inhibition of the RSK signaling prevents C/EPBb phosphorylation and stimulates the association of unphosphorylated C/
EBPb with active caspase 8 in Bleomycin-induced lung injury. A. Immunoblots for phospho-RSK, RSK, C/EBPb-phospho-Thr217, procaspase 8
and C/EBPb were performed on C/EBPb immunoprecipitates from lung protein lysates in an experiment conducted as described in (Fig. 1). Phospho-
RSK, RSK and phosphorylated C/EBPb were increased in C/EBPb immunoprecipitates in lungs of C/EBPb
wt treated with Bleomycin but not in C/EBPb-
Ala217 mice treated with Bleomycin or in the lungs of C/EBPb
wt treated with Bleomycin and the C/EBPb peptide. Active caspase 8 association with
unphosphorylated C/EBPb increased in C/EBPb-Ala217 mice treated with Bleomycin and in C/EBPb
wt mice treated with Bleomycin and the C/EBPb
peptide. C/EBPb was expressed as C/EBPbD154 also known as LIP. b-Actin was used to correct for lung lysate input. B. Pixel intensity was quantified
by the Odyssey Western Infrared Detection Method and Odyssey Visualization protocol as described in Methods. After Bleomycin administration, C/
EBPb and phosphorylated C/EBPb-Thr217 were induced several fold in the lungs of C/EBPb
wt mice (n: 6 per group; C/EBPb: 5.56+/20.52, P,0.0001;
phosphorylated C/EBPb-Thr217: 5.48+/20.37, P,0.0001), but not in the lungs of C/EBPb-Ala217 mice (n: 6 per group; C/EBPb: 1.20+/20.11, P=0.332;
phosphorylated C/EBPb-Thr217: 1.10+/20.17, P=0.510). There was an increased fold association between RSK and phosphorylated, activated RSK
with phosphorylated C/EBPb-Thr217 in lungs of C/EBPb
wt mice treated with Bleomycin (n: 6 per group; RSK: 4.85+/20.31, P,0.0001; phosphorylated,
activated RSK: 5.07+/20.37, P,0.0001) but not C/EBPb-Ala217 mice treated with Bleomycin (n: 6 per group; RSK: 0.87+/20.12, P=0.242;
phosphorylated, activated RSK: 1.01+/20.21, P=0.633). The fold association between C/EBPb with active caspase 8 was greater in the lungs from C/
EBPb-Ala217 mice after Bleomycin administration (n: 6 per group; active caspase 8: 5.65+/20.40, P,0.0001) than in the lungs from C/EBPb
wt mice
after Bleomycin administration (n: 6 per group; active caspase 8: 0.99+/20.12, P=0.362). After Bleomycin administration, mice that received the C/
EBPb peptide had a lower fold induction than control C/EBPb
wt mice after Bleomycin treatment in the expression of the following lung protein: (n: 7 ,
controls; n:6, Bleomycin and n:5, peptide ; C/EBPb: 1.23+/20.39, P=0.479 vs controls and P=0.0001 vs. Bleomycin; phosphorylated C/EBPb-Thr217:
1.03+/20.18 , P=0.258 vs. controls and P=0.0001 vs. Bleomycin). There was an increased fold association between RSK and phosphorylated,
activated RSK with phosphorylated C/EBPb-Thr217 in lungs of C/EBPb
wt mice treated with Bleomycin and the peptide (n: 7, controls; n:6, Bleomycin
and n:5, peptide; RSK: 2.17+/20.22, P,0.0001 vs. control and P,0.0001 vs Bleomycin ; phosphorylated, activated RSK: 1.44+/20.22, P,0.170 vs.
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progression of Bleomycin-induced lung injury and
fibrosis
Given the effective blocking of molecular pathways leading to
lung fibrosis in a Bleomycin model of lung injury and fibrosis by
the dominant negative C/EBPb-Ala217 transgene (Figures 1, 2
and 3) and the anti-fibrogenic effects of a dominant negative C/
EBPb peptide on cultured human lung fibroblasts (Figure 8), we
asked whether administration of the peptide could ameliorate the
lung injury and fibrosis induced by Bleomycin.
We have reported that the cell permeant Ac-KAla217VD-CHO
associates directly with procaspase 8 accelerating it self-processing
at picomolar concentrations [8],[10] and that 1 to 100 mg of the
cell permeant Ac-KAla217VD-CHO peptide administered intra-
peritoneally provided adequate systemic bioavailability with no
detectable toxicity in mice [8]. Therefore, as a proof of principle
we tested the effects of administering 40 mg of the peptide by
intratracheal instillation on day-2 and day-6 after receiving
Bleomycin on lung injury and fibrosis; more frequent intratracheal
instillations in Bleomycin-treated mice were not well tolerated.
Treatment of C/EBPb
wt mice with the peptide after receiving
Bleomycin on day-0, prevented progression of lung fibrosis
compared to control mice treated only with Bleomycin. At day-
21, there was a marked inhibition of lung fibrosis judging by the
trichrome stain and Sirius red stain (Figure 1A and 1B). Control
mice had moderate to severe fibrosis (mean fibrosis score: 2.8+/
20.4; n: 10) while mice that received the C/EBPb peptide had a
moderate degree of lung fibrosis (mean fibrosis score: 2.0+/20.7;
n:5 ;P=0.048; Wilcoxon U Test).
We confirmed these findings by quantitative analysis of lung
collagen with the Sirius red, collagen type 1 and hydroxyproline
assays [8]. Lung collagen content increased approximately 2- to 8-
fold from baseline in C/EBPb
wt mice treated with Bleomycin
while remaining closer to baseline in C/EBPb
wt mice treated with
Bleomycin and the C/EBPb peptide (P,0.001 for all measure-
ments). The specific fold changes in C/EBPb
wt mice treated with
Bleomycin and the C/EBPb peptide included : Sirius red collagen-
binding (0.94+/20.2, P=0.80); collagen type 1 (1.1+/20.2,
P=0.934); and hydroxyproline (3.1+/21.0, P=0.002; n: 5; for
all groups) (Figure 1C, 1D and 1E).
controls and P,0.0001 vs Bleomycin). The fold association between C/EBPb with active caspase 8 was greater in the lungs from C/EBPb
wt mice
treated with the Ac-KAla217VD-CHO peptide after Bleomycin administration (n: 5; active caspase 8: 5.65+/20.40, P,0.0001) that in the lungs from C/
EBPb
wt mice after Bleomycin administration.
doi:10.1371/journal.pone.0025497.g006
Figure 7. Induction and co-localization of active RSK and C/EBPb-PhosphoThr217 in Bleomycin-induced lung fibrosis. Mice were
treated with Bleomycin as described in (Fig. 1) and confocal microscopy was performed as described in Methods. Activated RSK-PhosphoSer380 (red)
and C/EBPb-PhosphoThr217 (green) were induced and co-localized at day-21 in the lungs of C/EBPb
wt treated with Bleomycin, but not in C/EBPb-
Ala217 mice treated with Bleomycin or in the lungs of C/EBPb
wt treated with Bleomycin and the C/EBPb peptide. Nuclei are identified with TO-PRO-3
(blue). Only background staining was observed when omitting the first antibody. The bar represents 50 mm.
doi:10.1371/journal.pone.0025497.g007
C/EBPb Phosphorylation and Lung Injury
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25497C/EBPb Phosphorylation and Lung Injury
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e25497In agreement with the results observed after Bleomycin
treatment in mice expressing the C/EBPb-Ala217 transgene,
treatment of C/EBPb
wt mice with the C/EBPb peptide
ameliorated other effects of Bleomycin and it was similar to
control untreated with Bleomycin: i) expression of lung fibrogenic
indicators such as a-SMA protein (1.0+/20.18, P=0.428), and
TGF-b1 protein (1.1+/20.17, P=0.793) (Figure 2); and ii)
recruitment of CD68
+ monocytes/macrophages and CD45
+ bone
marrow-derived fibrocytes to the lung (Figure S2 and S3).
Also we found that C/EBPb
wt mice that received the C/EBPb
peptide had less lung injury than control C/EBPb
wt mice after
Bleomycin treatment, judging by the SFPC expression by confocal
microscopy (Figure 3A) and quantitative immunoblots (n: 5;
0.78+/20.05 vs 0.04+/20.25; P=0.008) (Figure 3B and 3C).
The expression of SFPC protein was decreased from baseline by
Bleomycin treatment in animals receiving the peptide (P=0.0019)
(Figure 3B and 3C).
Similarly, we found that the protein expression of cytokines
interleukin (IL-1)-a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, TNF-a,
IFN-c and GM-CSF was lower in the lungs from C/EBPb
wt mice
that received the C/EBPb peptide than in the lungs from control
C/EBPb
wt mice after Bleomycin treatment (n:3 per group; P,0.05
for all cytokines) (Figure 4).
After Bleomycin administration, mice that received the C/
EBPb peptide had a much lower fold induction than control C/
EBPb
wt mice after Bleomycin treatment in the expression of the
following lung protein: (n:7, controls; n:6, Bleomycin and n:5,
peptide; C/EBPb: 1.23+/20.39, P=0.479 vs controls and
P=0.0001 vs Bleomycin; phosphorylated C/EBPb-Thr217:
1.03+/20.18, P=0.258 vs controls and P=0.0001 vs Bleomycin)
(Figure 6). These studies also demonstrated the increased fold
association between RSK and phosphorylated, activated RSK
with phosphorylated C/EBPb-Thr217 in lungs of C/EBPb
wt mice
treated with Bleomycin and the peptide (n:7, controls; n:6,
Figure 9. Increased expression of C/EBPb-PhosphoThr266 in activated lung myofibroblasts of human lung fibrosis. Representative
confocal microscopy of 2 IPF patients with severe lung fibrosis and 2 matched control subjects. C/EBPb-PhosphoThr266 (in red) and a-SMA (in green)
were present in activated LMF only in lungs of patients with lung fibrosis (lower panel). Co-localization of C/EBPb-PhosphoThr217 and a-SMA is
shown in white/yellow (merge). Nuclei are identified with TO-PRO-3 (blue). The bar represents 50 mm.
doi:10.1371/journal.pone.0025497.g009
Figure 8. Inhibition of the RSK signaling prevents C/EPBb phosphorylation and stimulates apoptosis in activated lung
myofibroblasts. A. Immunoblots for RSK, C/EBPb-phospho-Thr217, procaspase 8 and C/EBPb were performed on C/EBPb immunoprecipitates
from activated primary human LMF lysates as described in Methods. RSK and phosphorylated C/EBPb were induced in activated LMF but decreased in
activated LMF treated with the ERK1/2 inhibitor (10 mg for 24 hr) or with the C/EBPb peptide (200 mg for 24 hr). Inactive procaspase 8 was associated
with phosphorylated C/EBPb in untreated, activated LMF, while active caspase 8 was associated with unphosphorylated C/EBPb in activated LMF
treated with the ERK1/2 inhibitor or with the C/EBPb peptide. Human LMF expressed full-length C/EBPb from the second AUG [35]. b-Actin was used
to correct for lung lysate input. We performed single analysis of the samples. Results from triplicate samples of two independent experiments are
shown. B. The ERK1/2 inhibitor decreased the fold association of RSK with C/EBPb (n: 6 per group; 0.07+/20.01, P,0.0001), and the fold expression of
C/EBPb (n: 6 per group; 0.05+/20.006, P,0.0001) and C/EBPb-PhosphoThr266 (n: 6 per group; 0.33+/20.078, P,0.0001) in activated, human lung
fibroblasts. There was also an increased fold association between unphosphorylated human C/EBPb and active caspase 8 (n: 6 per group; active
caspase 8; 5.70+/20.59, P,0.0001). The cell permeant Ac-KAla217VD-CHO peptide also inhibited C/EBPb expression (n: 6 per group; 0.12+/20.01,
P,0.0001), the phosphorylation of C/EBPb-Thr266 (n: 6 per group; 0.17+/20.03, P,0.0001), the association of RSK with C/EBPb (n: 6 per group; 0.24+/
20.08, P,0.0001) and increased the association of RSK with C/EBPb (n: 6 per group; 0.24+/20.08, P,0.0001). We performed single analysis of the
samples. C. a-SMA and TGF-b were induced in activated LMF but the expression of these fibrogenic genes was inhibited by treatment with the ERK1/
2 inhibitor (10 mg for 24 hr) or with the peptide (200 mg for 24 hr). b-Actin was used to correct for lung lysate input. Representative results from two
independent studies. D. The ERK1/2 inhibitor decreased the fold expression of a-SMA (n: 6 per group; 0.24+/20.11, P,0.0001) and TGF-b1 (n: 6 per
group; 0.14+/20.02, P,0.0001). The cell permeant Ac-KAla217VD-CHO peptide also inhibited the fold expression of a-SMA (n: 6 per group; 0.24+/
20.11, P,0.0001) and TGF-b1 (n: 6 per group; 0.14+/20.02, P,0.0001). We performed single analysis of the samples. E. Annexin-V-PE binding in vivo
in activated LMF was increased after treatment with the ERK1/2 inhibitor (20 mg for 8 hr) or with the peptide (200 mg for 24 hr). Values are the
percentage of cells expressing annexin-V-PE binding as described in Methods. Activated, human lung fibroblasts treated with the ERK1/2 inhibitor (n:
6; 66.33+/25.68%, P,0.0001) or with the Ac-KAla217VD-CHO peptide (n: 6; 61.00+/29.27%, P,0.0001) displayed increased percent annexin-V
binding compared to control (n: 6; 4.15+/20.94%). We performed single analysis of the samples. Results from triplicate samples of three independent
experiments are shown.
doi:10.1371/journal.pone.0025497.g008
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control and P,0.0001 vs Bleomycin ; phosphorylated, activated
RSK: 1.44+/20.22, P,0.170 vs controls and P,0.0001 vs
Bleomycin) (Figure 6). Phosphorylated, activated RSK was co-
localized with phosphorylated C/EBPb-Thr217 by confocal
microscopy in lungs of C/EBPb
wt mice treated with Bleomycin
but not in the lungs of these animals when they received also
treatment with the peptide (Figure 7).
We found that the fold association between C/EBPb with active
caspase 8 was greater in the lungs from C/EBPb
wt mice treated
with the Ac-KAla217VD-CHO peptide after Bleomycin admin-
istration (n: 5; active caspase 8: 5.65+/20.40, P,0.0001) that in
the lungs from C/EBPb
wt mice after Bleomycin administration (n:
6; active caspase 8: 0.99+/20.12, P=0.362) (Figure 6). Also we
found increased protein expression of RIP, a member of the
caspase 8 complex II in the lungs of C/EBPb
wt mice treated with
the peptide mice after Bleomycin administration (Figure S4).
Increased expression of active RSK and C/EBPb-
PhosphoThr266 in activated LMF of human lung fibrosis
To assess the relevance to human lung fibrosis of the cellular
and animal models of liver fibrosis, we analyzed, in preliminary
studies, the role of activated RSK and phosphorylated C/EBPb on
Thr266 (identical to mouse Thr217 phosphoacceptor) as possible
mechanisms leading to increased lung fibrosis in two patients with
severe idiopathic lung fibrosis. Lung biopsies from patients
afflicted with severe Idiopathic Pulmonary Fibrosis displayed a
high level expression of both active, phosphorylated human C/
EBPb on Thr266 and phosphorylated RSK (that co-localized in
activated a-SMA
+ LMF within the fibrous tissue) (Figures 9 and
S5), compared with samples from two matched control patients as
identified by confocal scanning microscopy with specific antibodies
against RSK-PhosphoSer380, C/EBPb-PhosphoThr266, and a-
SMA for LMF [1].[7],[10]. Most of the activated RSK-
PhosphoSer380 appears to be nuclear as reported previously for
activated liver myofibroblasts [10] (Figure S5).
Thus, our findings in lung biopsies from patients with lung
fibrosis are congruent with the results from cellular and animal
models indicating that RSK induction and its phosphorylation of
mouse C/EBPb-Thr217 or human C/EBPb-Thr266 in activated
lung fibroblasts may be important in the development of human
lung injury and fibrosis.
Discussion
In this study, we have identified part of the molecular signaling
responsible for the decreased lung fibrogenic response to
Bleomycin reported in C/EBPb
ko mice [9]. Collectively, our
findings strongly suggest, but do not definitively prove, that the
RSK phosphoacceptor site KAKKThrVDK in C/EBPb , which is
identical in mouse-Thr217 and human-Thr266 [15], is critical for
lung injury and fibrogenesis in mice. This study also suggests that
blocking the RSK-C/EBPb-Thr217 phosphorylation pathway
with either a single point mutation (Ala217), dominant negative
transgene or a blocking peptide containing the mutated phos-
phoacceptor ameliorates the progression of lung injury and fibrosis
induced by Bleomycin in mice. Inhibition C/EBPb-Thr217
phosphorylation appears to affect lung fibrogenesis directly, by
inhibiting LMF activation and indirectly, by reducing lung injury.
These results are novel for lung injury and fibrosis and congruent
with the role of the RSK-C/EBPb-Thr217 phosphorylation
pathway in liver fibrogenesis that we proposed [8],[10],[37].
The lung toxin Bleomycin induced severe lung fibrosis in C/
EBPb
wt mice but not in mice expressing C/EBPb-Ala217, a non-
phosphorylatable transgene, as detected by several complementary
morphological, semi quantitative and quantitative assays. Blocking
phosphorylation of C/EBPb-Thr217 with the C/EBPb-Ala217
transgene (Figures 5 and 6) was associated with a decrease in the
lung fibrotic response to Bleomycin (Figure 1) and with a
decreased expression of the lung fibrogenic indicators a-SMA
(expressed in activated LMF) and TGF-b1 (a fibrogenic cytokine)
[7],[27] (Figure 2). Given the potential confounding effects of
strain variation on the development of pulmonary fibrosis induced
by a single intratracheal administration of Bleomycin [25], all mice
used in this study were of identical genetic background and back-
crossed to the parental wild-type inbreed FVB mice for at least 10
generations.
Because lung injury and inflammation may induce lung fibrosis
[1],[7] we assessed the degree of lung injury induced by
Bleomycin. In response to Bleomycin treatment, on day-13 we
found decreased lung injury (as assessed by SFPC protein
expression in the lungs) and inflammation (as assessed by the
presence of CD68
+ and CD45
+ cells as well as cytokine protein
expression in the lungs) in mice expressing the C/EBPb-Ala217
transgene (Figures 3, S2, S3 and 4). Our results suggest that
resistance to lung injury may contribute to the prevention of lung
fibrosis in C/EBPb-Ala217 mice and are consistent with the
proposed role of lung injury in the development of lung fibrosis
[7],[30]. Indeed, inhibition of SFPC production by type II
pneumocytes is a sensitive and specific indicator of alveolar
epithelial lung injury in humans and animals [30],[31]. Some
familial forms of lung fibrosis are associated with mutations in the
SFPC gene [38], and mice lacking SFPC had greater lung
inflammation and fibrosis after Bleomycin treatment [39]. Further,
surfactant administration including SFPC to the lungs has
dramatically improved the lung injury and inflammation of
preterm infants with respiratory distress syndrome [40]. We have
shown that blocking the phosphorylation of C/EBPb-Thr217 by
expressing the C/EBPb-Ala217 transgene during a toxic injury
induces apoptosis of activated liver myofibroblasts [8],[10] and of
activated lung myofibroblasts (Figures 6 and 8) but not of
hepatocytes [8],[10] or pneumocytes (Figure 3) . This effect is
most likely related to the check-point of activated myofibroblasts
since neither quiescent liver myofibroblasts nor hepatocytes are
affected by the induction of apoptosis [10].
We have reported that the cell permeant, dominant negative C/
EBPb peptide, Ac-KAla217VD-CHO, associates directly with
procaspase 8 accelerating it self-processing at picomolar concen-
trations [8],[10]. We have also reported that 1 to 100 mg of the cell
permeant Ac-KAla217VD-CHO peptide administered intraperi-
toneally provided adequate systemic bioavailability with no
detectable toxicity in mice [8]. Therefore, as a proof-of-principle
we tested the effects of administering 40 mg of the peptide by
intratracheal instillation on day-2 and day-6 on lung injury and
fibrosis; more frequent intratracheal instillations in Bleomycin
treated mice were not well tolerated.
Treatment of C/EBPb
wt mice with the C/EBPb peptide on
day-2 and day-6 after receiving Bleomycin on day-0 also
prevented progression of lung injury and fibrosis compared to
control mice treated only with Bleomycin (Figures 1, 2, 3 and
4). These results also support the role of phosphorylated C/EBPb-
Thr217 in lung injury and fibrosis. A more comprehensive
pharmacokinetic and pharmacodynamics analysis would be
required to fully understand the effects of the C/EBPb peptide
on lung injury and fibrosis. This approach will necessitate the
development of other forms of administering the peptide to
animals with lung injury.
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phosphorylation of C/EBPb are also critical in animal models
that reflect other causes of human lung fibrosis, such as radiation-
induced pneumonitis and fibrosis [18]. Any one of these studies
will require as extensive an analysis as that performed with the
Bleomycin model of lung fibrosis.
We found that mice expressing the C/EBPb-Ala217 transgene
were refractory to the induction of LMF activation by Bleomycin
treatment. After Bleomycin administration, C/EBPb was phos-
phorylated on Thr217 in LMF of C/EBPb
wt mice, but not in LMF
of C/EBPb-Ala217 mice (Figures 5 and 6). Moreover,
Bleomycin treatment induced the apoptotic cascade in LMF in
the lungs of C/EBPb-Ala217 mice, but not C/EBPb
wt mice, as
determined by the presence of active caspase 8 and RIP
(Figures 6 and S4). We have shown that C/EBPb-Ala217
peptides directly activate procaspase 8 at picomolar concentrations
in cell-free systems [10], explaining perhaps the activation of
caspase 8 in the lungs of C/EBPb-Ala217 mice 21 days after the
Bleomycin exposure.
Also we found that inhibition of the MAPK, ERK1/2, RSK
signaling (with ERK1/2 inhibitor or a dominant negative C/
EBPb peptide acting immediately upstream of C/EBPb phos-
phorylation) in cultured, activated human LMF induces the
apoptotic pathway. The apoptotic induction was identified by
increased caspase 8 activation and annexin-V binding to
phosphatidylserine in plasma membranes, an early indicator of
apoptosis [10] (Figure 8A, 8B and 8E). ERK1/2 or RSK
inhibitors also blocked expression of fibrogenic indicators a-SMA
and TGF-b1 in cultured, activated human LMF (Figure 8C and
8D). Collectively, these data in cultured, activated human LMF
supports the hypothesis that the MAPK, ERK1/2, RSK signaling
upstream of C/EBPb phosphorylation is important for lung
fibrogenesis. These findings would be enhanced by demonstrating
that ex vivo activation of LMF from both C/EBPb-Ala217
transgenic mice and from control C/EBPb
wt mice (after treatment
in culture with ERK1/2, or dominant negative C/EBPb-Ala217
peptides) also induces the apoptotic cascade, as we reported with
liver myofibroblasts [10]. However, isolation and characterization
of LMF from the different animal models will require extensive
additional methodological validation and investigation.
C/EBPb protein expression was induced by Bleomycin
treatment in the lungs of C/EBPb
wt mice but not in the lung of
C/EBPb-Ala217 transgenic mice (Figure 6), suggesting that lung
C/EBPb protein expression is linked to lung injury/fibrogenesis
and/or requires RSK activity, which is suppressed by the C/
EBPb-Ala217 transgene (Figure 6). It remains to be determined
what are the mechanisms modulating C/EBPb expression under
these experimental conditions. We and others have reported that
the expression of C/EBPb is regulated both at the transcriptional
and post-transcriptional levels [41]–[43]. For example, the size of
the C/EBPb mRNA pool is rapidly increased by LPS and IL-1
indicating a transcriptional activation of c/ebpb or increased C/
EBPb mRNA stability [42]. Given the inflammatory response
elicited in Bleomycin-induced lung injury it is plausible that this
mechanism is operative in these animals. We reported that mRNA
levels in lung result in a rate of synthesis of C/EBPb protein ,100-
fold less than that of the liver [41], suggesting a less efficient lung-
specific translational regulation of C/EBPb [44] through repres-
sion of translation from the C/EBPb mRNA in the lung [43].
Perhaps, de-repression of C/EBPb mRNA translation occurs in
Bleomycin-induced lung injury.
C/EBPbD154 (also known as LIP), an alternative, shorter
translation product initiated at the third AUG codon of the C/
EBPb mRNA [35], was expressed in the lungs of C/EBPb
wt mice
after Bleomycin treatment (Figure 6A). The ratio of C/EBPb:C /
EBPbD154 may affect cell proliferation and differentiation, since it
changes during development [35] and in LPS-mediated acute-
phase response [43]. It is unknown whether this lung C/EBPb
mRNA translational regulation also occurs in human lung injury.
However, in preliminary studies we found that C/EBPbD154 was
also the main translation product in the lungs of patients with IPF
(unpublished observations). In primary activated human LMF, C/
EBPb full length was also expressed as a lesser translation product
initiated at the second AUG codon of the C/EBPb mRNA [35]
(Figure 8A). The mechanisms responsible for and the significance
of expressing C/EBPbD154 remain to be elucidated.
C/EBPb-Ala217 was co-localized with caspase 8 and induced
the apoptotic cascade in activated, mouse and human LMF. The
combined results suggest, but do not prove, a functional link
between inactive RSK and the active caspase 8 complex II.
Further, we reported the association between inactive RSK and
active caspase 8 with C/EBPb-Ala217 or unphosphorylated C/
EBPb, suggesting also a physical link [10]. However, identification
of a putative structural RSK/caspase 8 complex would require
crystallographic analysis.
C/EBPb-Ala217 mice have a marked decrease in lung injury
and inflammation on day-13 after Bleomycin treatment when
compared to control C/EBPb
wt mice (Figures 3 and 4). These
findings are supported by our previous report on the inhibitory
effect of C/EBPb-Ala217 on macrophage activation in culture
[17]. C/EBPb appears to be a critical signaling molecule for
macrophages since its expression is dramatically increased during
differentiation of these cells, and it is induced by macrophage
modulators (LPS, IL-1, G-CSF, TGFb, vitamin D, retinoic acid)
[45],[46]. We have proposed a role for phosphorylated C/EBPb-
Thr217 on the modulation of macrophage function and survival
following their activation by tissue injury [17]. This hypothesis is
congruent with the fact that expression of the dominant positive
phosphorylation mimic C/EBPb-Glu217 [15] enhances function
and survival of macrophages [17], while C/EBPb
ko macrophages
display defective bacterial killing and tumor cytotoxicity [16]. In
addition, the Bleomycin-induced protein expression of inflamma-
tory cytokines (IL-1-a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, TNF-a,
IFN-c and GM-CSF) was ameliorated in the lungs of C/EBPb-
Ala217 transgenic mice as well as in the lungs of C/EBPb
wt mice
receiving the peptide. Most likely, these findings reflect the role of
C/EBPb-Thr217 phosphorylation in enhancing transcriptional
activity, without increasing DNA-binding affinity, from cytokine
promoters as we reported for the corresponding rat C/EBPb-
Ser105 phosphorylation [47].
Analysis of lung macrophage activation into pro-inflammatory
M1 and/or anti-inflammatory M2 phenotypes [48] in animal
models and in human lung injury will be required to elucidate the
mechanisms responsible for lung injury and inflammation
mediated by mouse C/EBPb-Thr217 or human C/EBPb-
Thr266. Additional sequential studies after Bleomycin exposure
and in other animal models would be needed to discriminate
whether decreased lung inflammation and injury contributes
significantly to the inhibition of lung fibrosis in C/EBPb-Ala217
mice. A corollary of our study is that mice expressing the dominant
positive C/EBPb-Glu217 transgene would be more susceptible to
myofibroblast cell activation and lung fibrosis induced by lung
injury and inflammation.
Although the specific association between C/EBPb-Phos-
phoThr217 and inactive procaspase 8 is linked to the inhibition
of active caspase 8 [8],[10] the precise molecular mechanisms by
which phosphorylated C/EBPb prevents the lung injury-induced
apoptotic cascade in LMF have not been characterized yet.
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such as p53 [49] or the activation of survival proteins, such as
MnSOD [50], or FLIP [51]. Alternatively, granzyme B rather
than caspase 8 could be the major target of phosphorylated C/
EBPb-Thr217, as we suggested previously for liver myofibroblast
apoptosis/survival [8],[10]. However, these potential mechanisms
will have to be assessed experimentally in models of lung fibrosis.
These results suggest that phosphorylation of C/EBPb-Thr266
(RSK phosphoacceptor) may be an important signaling pathway
in human lung fibrosis. Lungs from patients afflicted with severe
IPF, displayed a high level expression of both active, phosphor-
ylated RSK and phosphorylated C/EBPb-Thr266 co-localized in
activated LMF within the fibrous tissue, compared with samples
from control patients (Figures 9 and S5). Thus, our findings in
lung biopsies from patients with lung fibrosis are consistent with
the hypothesis we developed in cellular and animal models
implicating RSK activation and its phosphorylation of C/EBPb in
activated LMF in the development of human lung fibrosis.
Our data indicate that the RSK-C/EBPb phosphorylation
pathway may be critical for the progression of lung injury to lung
fibrosis in the Bleomycin animal model and that it is activated in
human lung fibrosis.
Clinical Implications
This study suggest that blocking the RSK-C/EBPb phosphor-
ylation pathway inhibits fibrogenesis directly, by inhibiting LMF
activation and indirectly, by reducing lung injury. There is no
available effective treatment for lung fibrosis.
It is premature to assess whether this signaling pathway could be
a potential target in the prevention and treatment of lung injury
and fibrosis. Both lack of progression of lung fibrosis, as we
documented in our study, as well as regression of lung fibrosis (a
necessary aim of future investigations) in spite of continued lung
injury are considered important clinical aims for patients with
chronic lung disease and lung fibrosis [1],[5]–[7].
Finally, blocking the progression of lung fibrosis may decrease
the need for lung transplantation since IPF is a main indication for
lung transplants worldwide [2].
Materials and Methods
Ethics Statement
The human protocol was approved by the University of
California, San Diego Human Protection Program project #
100380X, Project ID 1155365, IRB Protocol: 10-0380. For this
research involving human participants, informed consent was
exempted since the data were analyzed anonymously. All clinical
investigation has been conducted according to the principles
expressed in the Declaration of Helsinki. The animal studies were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the San Diego VA Health
Care System IACUC Protocol: 08-046.
Animal Procedures
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the San Diego VA Health Care System. All
tracheal instillations were performed under anesthesia, and all
efforts were made to minimize suffering. The mice were given an
IP injection of rodent anesthesia (0.4 ml/100 g of 50 mg/kg
ketamine; 5 mg/kg xylazine; and 1 mg/kg acepromazine). We
administered Bleomycin (2 U/kg in 50 ml saline by intratracheal
instillation) or saline (50 ml) once to C/EBPb
wt and C/
EBPbAla217 mice [8] (23–27 g). In other experiments, C/EBPb
wt
mice (25 g) each received Bleomycin (2 U/kg by intratracheal
instillation) once but also received the cell permeant C/EBPb (Ac-
K-Ala217-V-D-CHO) peptide (American Peptide; Sunnyvale,
CA) [10] (40 mg by intratracheal instillation on day-2 and day-
6). Animals were sacrificed on day 13 or on day-21 after the
Bleomycin treatment.
Construction of C/EBPb-Ala217 mice
Transgenic mice expressing C/EBPb-Ala217, a dominant
negative, nonphosphorylatable mutation of the C/EBPb-Thr217
phosphoacceptor, were generated as described previously [10] and
back-crossed to the parental wild-type inbreed FVB mice for .10
generations. The mouse C/EBPb cDNA was amplified by PCR to
mutate Thr217. The primers used to mutate Thr217 to Ala217
were S 59-GCC AAG GCC AAG AAG GCG GTG GAC AAG
CTG AGC -39 and AS 59-GCT CAG CTT GTC CAC CGC
CTT CTT GGC CTT GGC -39. C/EBPb was removed from
pEVRF0 with Apa I and Nhe I and cloned into pHM6 vector
(Boehringer-Mannheim, cat. # 1814664) in order to add an RSV
promoter upstream to the C/EBPb start site. C/EBPb was
removed from this new construct with Bsa I and Bsp. The 982 bp
insert was cloned into mammalian vector pOP13CAT (Stratagene)
from which the CAT portion had been previously removed. DNA
for pronuclear injection was purified over a CsCl gradient and
digested with Ssp I and EclHK I. The 3.6 Kb fragment was
separated on gel electrophoresis on a 0.8% gel with no Ethidium
Bromide. The appropriate band was removed and electro eluted
from the gel using the Elutrap apparatus from Schleicher &
Schuell. The eluted DNA was purified with a Qiagen-20 column,
precipitated with isopropanol and dissolved in 7.5 mM TRIS
pH 7.4, 0.15 mM EDTA. All solutions were prepared with tissue
grade water, endotoxin tested (Gibco). The DNA was dialyzed and
injected into fertilized ova at a concentration of 1.8 mg/ml
(Transgenic Mouse Core Facilities, University of California, San
Diego). The presence of the rsv gene was used to identify these
transgenic mice by PCR, and 3 positive mice resulted. The primer
sequences for the RSV PCR were custom designed (RSV.2271
TAGGGTGTGTTTAGGCGAAA sense and RSV.2510
TCTGTTGCCTTCCTAATAAG antisense). The PCR reagents
were all from Quiagen. Transgene-bearing founder mice were
mated with FVB mice. All founder mice produced viable offspring.
Cell cultures
Primary human lung fibroblasts isolated from normal human
lung parenchyma (Cell Applications; San Diego, CA) were
cryopreserved at first passage and can be cultured and propagated
at least 12 population doublings. Cells were freshly activated by
culturing on a collagen type 1 matrix as we described [52].
Activated LMF were untreated or treated for up to 24 hr with the
MAPK ERK1/2 inhibitor (10 or 20 mM) (Calbiochem 328006) or
treated for up to 24 hr with the Ac- K-Ala217-V-D-CHO peptide
(200 mM) [10] (American Peptide Co) and prepared for micros-
copy or cell lysates were immunoprecipitated with specific
antibodies.
Microscopy
Fluorescent labels were observed using antibodies against C/
EBPb, RSKPhosphoSer380, a-SMA (Abcam), SFPC (Abcam),
CD68 (Genway) , CD45 (Abcam), RIP (Santa Cruz Biotechnol-
ogy, Santa Cruz, California), or C/EBPb-PhosphoThr217 [10] in
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chromes utilized were Alexa 488 and Alexa 594. At least 100
cells were analyzed per experimental point [53]. We used TO-
PRO-3 (Molecular Probes, Eugene, Oregon) to analyze nuclear
morphology. The number of annexin-V (+) LMF was determined
by in vivo microscopy [10]. These values are reported as a
percentage of annexin-V (+) LMF. The degree of lung injury and
fibrosis was determined by using Hematoxylin/Eosin , Mallory’s
trichrome and Sirius red (under a polarized light) histochemistry
[26],[54]. The inter-observer agreement was .85%.
The program that we used for immunohistochemistry quanti-
tation was MetaMorph Offline, Universal Imaging Product
version 6.1. The MetaMorph Offline software package is an
accepted standard used to measure, analyze, and display data
acquired from a confocal system. We used the MetaMorph Offline
program to graph fluorescent intensities (integrated intensity;
summed over all of the pixels in the region) in a defined area from
the acquired confocal images. These data were exported directly
to Excel (Microsoft) for the calculations. At least five random fields
(6200) were analyzed per experimental point [28].
Lung Fibrosis
We determined the degree of lung fibrosis in coded samples. We
evaluated lung fibrogenesis employing the following methods as
previously described [8]: i) trichrome stain; ii) Sirius red stain; iii)
quantitative Sirius red collagen-binding assay; iv) quantitative
collagen type 1 assay; v) quantitative hydroxyproline assay; vi)
protein expression of a-smooth muscle actin (a-SMA); and vii)
protein expression of transforming growth factor (TGF)-b1.
Lung Inflammatory Cytokines
A multiplex protein cytokine detection system (Quansys
Biosciences, Logan, UT) was utilized in lung tissue lysates
according to the manufacturer’s protocol to determine IL-1-a,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, TNF-a, IFN-c and GM-CSF.
Values calculated from individual pixels using the Q-View Imager
system.
Immunoprecipitation and Immunoblots
Pre-cleared lung or LMF lysates were incubated for 2 h with
purified C/EBPb, C/EBPb-Phospho-Thr217, RSK, caspase 8
(Santa Cruz Biotechnology) , a-SMA, TGFb or b-actin (Abcam)
antibodies followed by the addition of A/G+ agarose (Santa Cruz
Biotechnology) for 12 h. The immunoprecipitation reactions each
contained 500 mg of total protein and 2 mg antibody (or purified
IgG pre-immune serum as negative control). Immunoprecipitates
were washed 3 times in 500 ml cell lysis buffer [41] and resolved
by SDS-PAGE, and detected by western blot [47],[55], following
the Odyssey Western Infrared Detection Method and Odyssey
Visualization protocol using purified antibodies against C/EBPb
(C-19; aa 258–276), RSK, a-SMA, TGFb, b-actin, procaspase 8
(PharMingen) and C/EBPb-PhosphoThr217(h266) [10].
Human Lungs
We obtained anonymous, de-identified lung samples from 2
patients with IPF and severe lung fibrosis (65-year old female and
61-year old male) and from 2 matched control subjects without
lung disease (65-year old female and 60-year old male) (Arseland
and ProSci).
Statistical Analysis
Results are expressed as mean (6 SD). The Student-t and the
Wilcoxon U tests were used to evaluate the differences of the
means between groups for parametric and non-parametric
populations, respectively, with a P value of ,0.05 as significant.
Supporting Information
Figure S1 RSK inhibition blocks lung injury induced by
Bleomycin. A. Mice were from the experiment described in
(Fig. 1). Analysis was performed on day-13. Representative
hematoxylin and eosin stain for lung injury. C/EBPb
wt mice
treated with Bleomycin developed severe lung injury. The C/
EBPb-Ala217 mice treated with Bleomycin had only minimal or
moderate lung injury. Treatment of C/EBPb
wt mice with the C/
EBPb peptide (on day-2 and day-6) after Bleomycin treatment
decreased the development of lung injury. The bars represent
50 mm.
(TIF)
Figure S2 Mice expressing the C/EBPb-Ala217 trans-
gene are resistant to Bleomycin-induced lung inflam-
mation. Mice were treated with Bleomycin and confocal
microscopy was performed as described in Methods. A. Activated
monocytes/macrophages, identified by confocal microscopy for
CD68
+ (green), were increased at day-13 in the lungs of C/EBPb
wt
mice treated with Bleomycin, but not in the lungs of C/EBPb-
Ala217 mice after treatment with Bleomycin or in the lungs of C/
EBPb
wt treated with Bleomycin and the C/EBPb peptide. Nuclei
are identified with TO-PRO-3 (blue). Only background staining
wasobserved when omitting the first antibody. Microscopy shown is
representative of each group. The bars represent 50 mm.
(TIF)
Figure S3 Induction CD45
+ cells in the lungs of Bleo-
mycin-treated C/EBPb
wt mice. Mice were treated with
Bleomycin as described in (Fig. 1) and confocal microscopy was
performed as described in Methods. CD45
+ (red) was induced and
co-localized at day-13 in the lungs of C/EBPb
wt treated with
Bleomycin, but not in C/EBPb-Ala217 mice treated with
Bleomycin or in the lungs of C/EBPb
wt treated with Bleomycin
and the C/EBPb peptide. Nuclei are identified with TO-PRO-3
(blue). Only background staining was observed when omitting the
first antibody. The bar represents 50 mm.
(TIF)
Figure S4 RIP is induced in the lungs of mice expressing
the C/EBPb-Ala217 transgene. Mice were treated with
Bleomycin as described in (Fig. 1) and confocal microscopy was
performed as described in Methods. RIP (red) was induced at day-
21 in the lungs of C/EBPb-Ala217 mice treated with Bleomycin
and in the lungs of C/EBPb
wt treated with Bleomycin and the C/
EBPb peptide, but not in C/EBPb
wt treated with Bleomycin.
Nuclei are identified with TO-PRO-3 (blue). Only background
staining was observed when omitting the first antibody. The bar
represents 50 mm.
(TIF)
Figure S5 Induction and co-localization of active RSK
and C/EBPb-PhosphoThr266 in human lung fibrosis.
Representative confocal microscopy of 2 IPF patients with severe
lung fibrosis and 2 matched control subjects. Activated LMF,
identified by confocal microscopy for their morphology and a-
SMA expression (as in Fig. 8) , displayed activated RSK-
PhosphoSer380 (red) and C/EBPb-PhosphoThr266 (green) in
lungs of IPF patients with severe lung fibrosis (lower panel) but not
in the lungs of control subjects (upper panel). Co-localization of
RSK-PhosphoSer380 and C/EBPb-PhosphoThr266 is shown in
yellow or white (merge). Nuclei are identified with TO-PRO-3
C/EBPb Phosphorylation and Lung Injury
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first antibody.
(TIF)
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